Melinta Therapeutics,'s Revenue in the fiscal year 2018 $ 96.43 millions
Melinta Therapeutics,'s Revenue in the fiscal year 2017 $ 33.86 millions
Melinta Therapeutics,'s Revenue in the fiscal year 2016 $ 18.02 millions
Melinta Therapeutics,'s Revenue in the fiscal year 2015 $ 27.31 millions
Melinta Therapeutics,'s Revenue in the fiscal year 2014 $ 15.22 millions
CEMP Revenue third quarter 2019 Y/Y Growth Comment
Melinta Therapeutics, Inc. reported drop in Revenue in the third quarter 2019 by -53.43% to $ 15.87 millions, from the same quarter in 2018. The fall in the third quarter 2019 Melinta Therapeutics, Inc.'s Revenue compares unfavorably to the Company's average Revenue doubling of 231.64%.
Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 228 other companies have achieved higher Revenue growth. While Melinta Therapeutics, Inc.' s Revenue meltdown of -53.43% ranks overall at the positon no. 4114 in the third quarter 2019.
CEMP Revenue ( Y/Y Growth %)
2019
2018
2017
2016
4th Quarter
December
-
739.01 %
-46.79 %
37.31 %
3rd Quarter
September
-53.43 %
968.34 %
-19.65 %
58.8 %
2nd Quarter
June
32.78 %
202.01 %
16.37 %
-32.28 %
1st Quarter
March
-5.12 %
-33.93 %
738.06 %
-80.8 %
FY
-
184.79 %
87.9 %
-
Financial Statements
Melinta Therapeutics,'s third quarter 2019 Revenue
Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019
Melinta Therapeutics,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
465.3 %
34.45 %
-100 %
(Mar 31 2015)
CEMP's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2019 Melinta Therapeutics, Inc. disclosed decrease in Revenue from the second quarter by -0.56% to $ 15.87 millions, from $ 15.96 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2019 Revenue, this plainly could not be substantial to rescue 's company achievement, Most analysts pointed out.
Within Major Pharmaceutical Preparations industry 155 other companies have achieved higher Revenue quarter on quarter growth. While Melinta Therapeutics,'s Revenue growth quarter on quarter, overall rank is 2453.
In the III. Quarter 2019 Melinta Therapeutics, Inc. disclosed decrease in Revenue from the second quarter by -0.56% to $ 15.87 millions, from $ 15.96 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2019 Revenue, this plainly could not be substantial to rescue 's company achievement, Most analysts pointed out.
Within Major Pharmaceutical Preparations industry 155 other companies have achieved higher Revenue quarter on quarter growth. While Melinta Therapeutics,'s Revenue growth quarter on quarter, overall rank is 2453.
Melinta Therapeutics,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Sep 30 2019)
12 Months Ending (Jun 30 2019)
12 Months Ending (Mar 31 2019)
12 Months Ending (Dec 31 2018)
12 Months Ending (Sep 30 2018)
Cumulative Revenue 12 Months Ending
$ 81.40
$ 99.61
$ 95.67
$ 96.43
$ 65.17
Y / Y Revenue Growth (TTM)
24.9 %
190.52 %
264.58 %
184.76 %
73.43 %
Year on Year Revenue Growth Overall
Ranking
# 769
# 608
# 0
# 0
# 0
Seqeuential Revenue Change (TTM)
-18.28 %
4.11 %
-0.79 %
47.96 %
90.09 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2449
# 88
# 0
# 0
# 0
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2019 period, Melinta Therapeutics,'s cumulative twelve months Revenue were $ 81 millions, company would post below average annual Revenue growth of 90.09% year on year, if the fiscal year would end at Sep 30 2019. A slow-down in the Melinta Therapeutics,'s Revenue growth from the 15.96% growth in Jun 30 2019.
In the Healthcare sector 171 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 608 to 769.
With the quarterly Revenue reported in the Sep 30 2019 period, Melinta Therapeutics,'s cumulative twelve months Revenue were $ 81 millions, company would post below average annual Revenue growth of -50.81% year on year, if the fiscal year would end at Sep 30 2019. A slow-down in the Melinta Therapeutics,'s Revenue growth from the 15.96% growth in Jun 30 2019.
In the Healthcare sector 171 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 608 to 769.
About Melinta Therapeutics, Revenue Growth Rates (CEMP), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
